CD40LG and myeloid sarcoma: When we analyzed the anti-HHV-6A/B IgM antibodies (Table 2), we found a trend for the reduction of the prevalence in MS patients treated with natalizumab, and a decrease of the mean titers with the different DMTs (p = 0.003); again, the greatest reduction was for natalizumab (p = 0.024).